Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Digestive Diseases and Sciences

Volumn 64, Issue 12, 2019, Pages 3402-3412

  Liu, Liang ^a,b   Li, Ping ^b,c   Liu, Yiqi ^a   Zhang, Yilian ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN SECOND PEOPLE S HOSPITAL   (China)

^c Tianjin Cardiovascular Diseases Institute   (China)

Author keywords

Meta analysis; Nonalcoholic fatty liver disease; Probiotics; Synbiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROBIOTIC AGENT; SYNBIOTIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER STIFFNESS; META ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; DIAGNOSTIC IMAGING; DIETARY SUPPLEMENT; ELASTOGRAPHY; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; METABOLISM; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DIETARY SUPPLEMENTS; ELASTICITY IMAGING TECHNIQUES; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS; SYNBIOTICS; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 85067638756     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-019-05699-z     Document Type: Review

References (42)

1. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132–138.
2. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism. 2016;65:1017–1025.
3. Miele L, Targher G. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Rev Gastroenterol Hepatol. 2015;9:1243–1245.
4. Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of nonalcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2013;28:142–147.
5. Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.
6. Miraghajani M, Zaghian N, Dehkohneh A, Mirlohi M, Ghiasvand R. Probiotic soy milk consumption and renal function among type 2 diabetic patients with nephropathy: a randomized controlled clinical trial. Probiotics Antimicrob Proteins. 2017;1:1–9.
7. Khalesi S, Johnson DW, Campbell K, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr. 2017;57:2037–2053.
8. Lavekar AS, Raje DV, Manohar T, Lavekar AA. Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Euroasian J Hepatogastroenterol. 2017;7:130–137.
9. Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatol Res. 2016;46:1226–1233.
10. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19:6911–6918.
11. Moher D, Liberati A, Tetzlaff J, Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
12. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley Online Library; 2008.
13. Saverymuttu SHJA, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J. 1986;292:13–15.
14. Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64:413–417.
15. Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with nonalcoholic fatty liver disease: a clinical trial. Int J Prev Med. 2016;7:59.
16. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97:7386–7393.
17. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.
18. Javadi L, Ghavami M, Khoshbaten M, Safaiyan A, Barzegari A, Gargari BP. The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial. Iran Red Crescent Med J. 2017;4:131–138.
19. Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in nonalcoholic fatty liver disease: a randomized clinical trial. Middle East J Dig Dis. 2017;9:150–157.
20. Ekhlasi G, Mohammadi RK, Agah S, et al. Do symbiotic and vitamin e supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2016;21:98.
21. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256–262.
22. Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545–553.
23. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–743.
24. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090–1095.
25. Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for nonalcoholic steatohepatitis: a pilot trial. J Dig Dis. 2017;18:698–703.
26. Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointest Liver Dis. 2018;27:41–49.
27. Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with nonalcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662–668.
28. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535–542.
29. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015;10:889–902.
30. Barengolts E. Gut microbiota, prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: review of randomized controlled trials. Endocr Pract. 2016;22:1224–1234.
31. Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–425.
32. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–2383.
33. Wen JF, Ye GL, Zhang HX, Ding JX, Chen SH. Clinical efficacy of bifidobacterium triple active bacteria combined with polyene phosphatidylcholine on NASH. China Mod Dr. 2014;52:5–13.
34. Wang W, Shi LP, Shi L, Xu L. Efficacy of probiotics on the treatment of nonalcoholic fatty liver disease. Zhonghua Nei Ke Za Zhi. 2018;57:101–106.
35. Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a probiotic and metformin on liver aminotransferases in nonalcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med. 2013;4:531–537.
36. Zhang Y, Hu C, Hong J, et al. Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2014;37:2804–2812.
37. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350.
38. Patrice DC, Nathalie MD. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546–1558.
39. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL# 3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540–543.
40. Wagnerberger S, Spruss A, Kanuri G, et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013;24:531–538.
41. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989–997.
42. Ting WJ, Kuo WW, Hsieh DJ, et al. Heat killed Lactobacillus reuteri GMNL-263 reduces fibrosis effects on the liver and heart in high fat diet-hamsters via TGF-β suppression. Int J Mol Sci. 2015;16:25881–25896.